{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T20:08:32Z","timestamp":1793909312328,"version":"4.8.0"},"reference-count":72,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["8237318"],"award-info":[{"award-number":["8237318"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.critrevonc.2026.105373","type":"journal-article","created":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T11:37:55Z","timestamp":1778758675000},"page":"105373","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["In vivo generation of CAR-T cells: Current obstacles, strategic solutions, and clinical translation"],"prefix":"10.1016","volume":"224","author":[{"given":"Ziyu","family":"Jiang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shichu","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenying","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4903-022X","authenticated-orcid":false,"given":"Jiannan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhigang","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.critrevonc.2026.105373_bib1","unstructured":"Anone. Immunosuppression in tumor immune microenvironment and its optimization from CAR-T cell therapy - PubMed. Accessed January 30, 2026. \u3008https:\/\/pubmed.ncbi.nlm.nih.gov\/36168626\/\u3009."},{"key":"10.1016\/j.critrevonc.2026.105373_bib2","unstructured":"Anone. In vitro-transcribed antigen receptor mRNA nanocarriers for transient expression in circulating T cells in vivo | Nature Communications. Accessed January 30, 2026. \u3008https:\/\/www.nature.com\/articles\/s41467-020-19486-2?utm_source=chatgpt.com\u3009."},{"key":"10.1016\/j.critrevonc.2026.105373_bib3","unstructured":"Anone. Synthetic biology approaches for improving the specificity and efficacy of cancer immunotherapy | Cellular & Molecular Immunology. Accessed February 1, 2026a. \u3008https:\/\/www.nature.com\/articles\/s41423-024-01153-x?utm_source=chatgpt.com\u3009."},{"key":"10.1016\/j.critrevonc.2026.105373_bib4","unstructured":"Anone. How nature can exploit nonspecific catalytic and carbohydrate binding modules to create enzymatic specificity | PNAS. Accessed January 31, 2026a. \u3008https:\/\/www.pnas.org\/doi\/10.1073\/pnas.1212034109\u3009."},{"key":"10.1016\/j.critrevonc.2026.105373_bib5","unstructured":"Anone. In vivo nano-engineering T cells for CAR-T therapy - ScienceDirect. Accessed April 25, 2026b. \u3008https:\/\/www.sciencedirect.com\/science\/article\/pii\/S0168365925009939?utm_source=chatgpt.com\u3009."},{"key":"10.1016\/j.critrevonc.2026.105373_bib6","unstructured":"Anone. Overcoming on-target, off-tumour toxicity of CAR T cell therapy for solid tumours - PubMed. Accessed February 1, 2026b. \u3008https:\/\/pubmed.ncbi.nlm.nih.gov\/36418477\/\u3009."},{"key":"10.1016\/j.critrevonc.2026.105373_bib7","unstructured":"Anone. In vivo human T cell engineering with enveloped delivery vehicles | Nature Biotechnology. Accessed January 31, 2026c. \u3008https:\/\/www.nature.com\/articles\/s41587-023-02085-z?utm_source=chatgpt.com\u3009."},{"key":"10.1016\/j.critrevonc.2026.105373_bib8","unstructured":"Anone. Phase I Study in NHL Use of Armored CAR T Cells May Be Feasible After Standard CAR T-Cell Failure - The ASCO Post. Accessed February 2, 2026c. \u3008https:\/\/ascopost.com\/issues\/june-25-2024\/phase-i-study-in-nhl-use-of-armored-car-t-cells-may-be-feasible-after-standard-car-t-cell-failure\/?utm_source=chatgpt.com\u3009."},{"key":"10.1016\/j.critrevonc.2026.105373_bib9","unstructured":"Anone. Closed System Automated Manufacturing \u2013 Benefits and Challenges - International Society for Cell & Gene Therapy. Accessed February 2, 2026d. \u3008https:\/\/www.isctglobal.org\/events\/event-description?CalendarEventKey=16180c97-51f8-4e81-8482-bb5383f6de27&Home=%2Fhome&utm_source=chatgpt.com\u3009."},{"key":"10.1016\/j.critrevonc.2026.105373_bib10","unstructured":"Anone. Leveraging CRISPR gene editing technology to optimize the efficacy, safety and accessibility of CAR T-cell therapy | Leukemia. Accessed January 31, 2026d. \u3008https:\/\/www.nature.com\/articles\/s41375-024-02444-y?utm_source=chatgpt.com\u3009."},{"key":"10.1016\/j.critrevonc.2026.105373_bib11","unstructured":"Anone. Engineering a streamlined virus-like particle for programmable tissue-specific gene delivery | Nature Communications. Accessed January 31, 2026e. \u3008https:\/\/www.nature.com\/articles\/s41467-025-64181-9?utm_source=chatgpt.com\u3009."},{"key":"10.1016\/j.critrevonc.2026.105373_bib12","unstructured":"Anone. Interius BioTherapeutics Doses First Patient with In Vivo CAR-T Therapy INT2104. MedPath. October 23, 2024. Accessed February 2, 2026e. \u3008https:\/\/trial.medpath.com\/news\/7c6c9eea1390fd20\/first-patient-dosed-with-in-vivo-gene-therapy-for-car-t-inside-precision-medicine\u3009."},{"key":"10.1016\/j.critrevonc.2026.105373_bib13","unstructured":"Anone. Lipid nanoparticles for engineering next generation CAR T cell immunotherapy - Nanoscale Horizons (RSC Publishing) DOI:10.1039\/D5NH00432B. Accessed February 2, 2026f. \u3008https:\/\/pubs.rsc.org\/en\/content\/articlehtml\/2025\/nh\/d5nh00432b?utm_source=chatgpt.com\u3009."},{"key":"10.1016\/j.critrevonc.2026.105373_bib14","doi-asserted-by":"crossref","unstructured":"Anone. The Future of Tissue-Targeted Lipid Nanoparticle-Mediated Nucleic Acid Delivery | MDPI. Accessed January 31, 2026f. \u3008https:\/\/www.mdpi.com\/1424-8247\/15\/7\/897?utm_source=chatgpt.com\u3009.","DOI":"10.3390\/ph15070897"},{"key":"10.1016\/j.critrevonc.2026.105373_bib15","unstructured":"Anone. In vivo CAR-T Therapy Challenges the Cancer Treatment Paradigm. Accessed February 2, 2026g. \u3008https:\/\/www.isctglobal.org\/telegrafthub\/blogs\/isct-head-office1\/2025\/10\/07\/scientific-spotlight-in-vivo-car-t-therapy-challen?utm_source=chatgpt.coma\u3009."},{"key":"10.1016\/j.critrevonc.2026.105373_bib16","doi-asserted-by":"crossref","unstructured":"Anone. T cell-specific non-viral DNA delivery and in vivo CAR-T generation using targeted lipid nanoparticles | Journal for ImmunoTherapy of Cancer. Accessed January 31, 2026i. \u3008https:\/\/jitc.bmj.com\/content\/13\/7\/e011759?utm_source=chatgpt.com\u3009.","DOI":"10.1136\/jitc-2025-011759"},{"key":"10.1016\/j.critrevonc.2026.105373_bib17","unstructured":"Anone. Non-viral chimeric antigen receptor (CAR) T cells going viral - ScienceDirect. Accessed February 1, 2026j. \u3008https:\/\/www.sciencedirect.com\/science\/article\/pii\/S2590018823000035?utm_source=chatgpt.com\u3009."},{"issue":"11","key":"10.1016\/j.critrevonc.2026.105373_bib18","doi-asserted-by":"crossref","DOI":"10.1002\/smll.202304378","article-title":"Vivo mRNA CAR T cell engineering via targeted ionizable lipid nanoparticles with extrahepatic tropism","volume":"20","author":"Billingsley","year":"2024","journal-title":"Small"},{"issue":"7","key":"10.1016\/j.critrevonc.2026.105373_bib19","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2025-011759","article-title":"T cell-specific non-viral DNA delivery and in vivo CAR-T generation using targeted lipid nanoparticles","volume":"13","author":"Bimbo","year":"2025","journal-title":"J. Immunother. Cancer"},{"issue":"9","key":"10.1016\/j.critrevonc.2026.105373_bib20","doi-asserted-by":"crossref","DOI":"10.1038\/nbt.3330","article-title":"Principles of nanoparticle design for overcoming biological barriers to drug delivery","volume":"33","author":"Blanco","year":"2015","journal-title":"Nat. Biotechnol."},{"issue":"9","key":"10.1016\/j.critrevonc.2026.105373_bib21","doi-asserted-by":"crossref","DOI":"10.1038\/nbt.3330","article-title":"Principles of nanoparticle design for overcoming biological barriers to drug delivery","volume":"33","author":"Blanco","year":"2015","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.critrevonc.2026.105373_bib22","unstructured":"Bot, A., Scharenberg, A., Friedman, K., , 2026. In vivo chimeric antigen receptor (CAR)-T cell therapy. Nat Rev Drug Discov. Published online September 30, 2025. Accessed January 15, 2026. https:\/\/www.nature.com\/articles\/s41573-025-01291-5."},{"issue":"26","key":"10.1016\/j.critrevonc.2026.105373_bib23","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2016-04-703751","article-title":"Toxicities of chimeric antigen receptor T cells: recognition and management","volume":"127","author":"Brudno","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2026.105373_bib24","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2024.105266","article-title":"Advancements and challenges in developing in vivo CAR T cell therapies for cancer treatment","volume":"106","author":"Bui","year":"2024","journal-title":"EBioMedicine"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105373_bib25","doi-asserted-by":"crossref","DOI":"10.1186\/s40164-025-00725-5","article-title":"vivo CAR-T cell engineering: concept, research progress, potential challenges and enhancement strategies","volume":"14","author":"Chen","year":"2025","journal-title":"Exp. Hematol. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105373_bib26","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2025-6097","article-title":"Targeted lnp delivery of an RNA gene writer In Vivo enables generation of functional CAR-T cells","volume":"146","author":"Cotta-Ramusino","year":"2025","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.critrevonc.2026.105373_bib27","doi-asserted-by":"crossref","DOI":"10.1016\/j.ymthe.2017.03.013","article-title":"Lipid nanoparticle systems for enabling gene therapies","volume":"25","author":"Cullis","year":"2017","journal-title":"Mol. Ther."},{"key":"10.1016\/j.critrevonc.2026.105373_bib28","doi-asserted-by":"crossref","unstructured":"Diez B., Calvi\u00f1o C., Fern\u00e1ndez-Garc\u00eda M., et al. Generation and GMP scale-up of human CAR-T cells using non-viral Sleeping Beauty transposons for B cell malignances. Molecular Therapy Methods & Clinical Development. 2025;33(1). Accessed February 1, 2026. \u3008https:\/\/www.cell.com\/molecular-therapy-family\/advances\/abstract\/S2329-0501\u3009(25)00020-8.","DOI":"10.1016\/j.omtm.2025.101425"},{"key":"10.1016\/j.critrevonc.2026.105373_bib29","doi-asserted-by":"crossref","DOI":"10.1146\/annurev-chembioeng-092120-092914","article-title":"Engineering next-generation CAR-T cells: overcoming tumor hypoxia and metabolism","volume":"13","author":"Gao","year":"2022","journal-title":"Annu. Rev. Chem. Biomol. Eng."},{"key":"10.1016\/j.critrevonc.2026.105373_bib30","doi-asserted-by":"crossref","DOI":"10.1186\/s40364-026-00899-y","article-title":"vivo engineering of CAR-T cells: delivery strategies and clinical translation","volume":"14","author":"Gao","year":"2026","journal-title":"Biomark. Res"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105373_bib31","doi-asserted-by":"crossref","DOI":"10.1186\/s40364-026-00899-y","article-title":"vivo engineering of CAR-T cells: delivery strategies and clinical translation","volume":"14","author":"Gao","year":"2026","journal-title":"Biomark. Res"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105373_bib32","doi-asserted-by":"crossref","DOI":"10.1186\/s13045-026-01787-6","article-title":"vivo CAR-T cell therapy: latest updates from 2025 ASH annual meeting","volume":"19","author":"Gao","year":"2026","journal-title":"J. Hematol. Oncol."},{"issue":"24","key":"10.1016\/j.critrevonc.2026.105373_bib33","doi-asserted-by":"crossref","DOI":"10.3390\/ijms252413685","article-title":"Current non-viral-based strategies to manufacture CAR-T cells","volume":"25","author":"Gehrke","year":"2024","journal-title":"Int. J. Mol. Sci."},{"issue":"5644","key":"10.1016\/j.critrevonc.2026.105373_bib34","doi-asserted-by":"crossref","DOI":"10.1126\/science.1088547","article-title":"LMO2-Associated Clonal T Cell Proliferation in Two Patients after Gene Therapy for SCID-X1","volume":"302","author":"Hacein-Bey-Abina","year":"2003","journal-title":"Science"},{"key":"10.1016\/j.critrevonc.2026.105373_bib35","doi-asserted-by":"crossref","DOI":"10.1002\/adma.202514370","article-title":"High-throughput in vivo screening using barcoded mRNA identifies lipid nanoparticles with extrahepatic tropism for in situ immunoengineering","author":"Hamilton","year":"2026","journal-title":"Adv. Mater."},{"issue":"12","key":"10.1016\/j.critrevonc.2026.105373_bib36","doi-asserted-by":"crossref","DOI":"10.1038\/s41578-021-00358-0","article-title":"Lipid nanoparticles for mRNA delivery","volume":"6","author":"Hou","year":"2021","journal-title":"Nat. Rev. Mater."},{"key":"10.1016\/j.critrevonc.2026.105373_bib37","doi-asserted-by":"crossref","unstructured":"Huang Y., Cao R., Wang S., Chen X., Ping Y., Zhang Y. n.d. In vivo CAR-T cell therapy: New breakthroughs for cell-based tumor immunotherapy. Hum Vaccin Immunother. 21(1).","DOI":"10.1080\/21645515.2025.2558403"},{"key":"10.1016\/j.critrevonc.2026.105373_bib38","doi-asserted-by":"crossref","unstructured":"Huang Y., Cao R., Wang S., Chen X., Ping Y., Zhang Y. n.d. In vivo CAR-T cell therapy: New breakthroughs for cell-based tumor immunotherapy. Hum Vaccin Immunother. 21(1).","DOI":"10.1080\/21645515.2025.2558403"},{"key":"10.1016\/j.critrevonc.2026.105373_bib39","unstructured":"Hunter T.L., Zhang Y., Matsuda D., et al. n.d. In vivo CAR T cell generation to treat cancer and autoimmune disease."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105373_bib40","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMra1706169","article-title":"Chimeric antigen receptor therapy","volume":"379","author":"June","year":"2018","journal-title":"N. Engl. J. Med"},{"key":"10.1016\/j.critrevonc.2026.105373_bib41","doi-asserted-by":"crossref","DOI":"10.1016\/j.omto.2022.03.009","article-title":"CAR T cell therapy and the tumor microenvironment: Current challenges and opportunities","volume":"25","author":"Kankeu Fonkoua","year":"2022","journal-title":"Mol. Ther. Oncolytics"},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105373_bib42","doi-asserted-by":"crossref","DOI":"10.1039\/D3LC00622K","article-title":"A. expanding CAR-T cell immunotherapy horizons through microfluidics","volume":"24","author":"Kim","year":"2024","journal-title":"Lab a Chip"},{"issue":"12","key":"10.1016\/j.critrevonc.2026.105373_bib43","doi-asserted-by":"crossref","DOI":"10.1111\/cts.70101","article-title":"Translational PK\u2013PD model for in vivo CAR-T-cell therapy delivered using CAR mRNA-loaded polymeric nanoparticle vector","volume":"17","author":"Kim","year":"2024","journal-title":"Clin. Transl. Sci."},{"issue":"11","key":"10.1016\/j.critrevonc.2026.105373_bib44","article-title":"Universal CAR-T cell therapy for cancer treatment: advances and challenges","volume":"33","author":"Lei","year":"2025","journal-title":"OR"},{"key":"10.1016\/j.critrevonc.2026.105373_bib45","article-title":"Global manufacturing of CAR T cell therapy","volume":"4","author":"Levine","year":"2016","journal-title":"Mol. Ther. Methods Clin. Dev."},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105373_bib46","doi-asserted-by":"crossref","DOI":"10.1038\/s41576-019-0205-4","article-title":"Engineering adeno-associated virus vectors for gene therapy","volume":"21","author":"Li","year":"2020","journal-title":"Nat. Rev. Genet"},{"key":"10.1016\/j.critrevonc.2026.105373_bib47","doi-asserted-by":"crossref","unstructured":"Li X., Song S. \u201cn.d. Dissecting the role of T cell exhaustion in cancer progression: a multifaceted approach\u201c. Front Immunol. 16.","DOI":"10.3389\/fimmu.2025.1646292"},{"issue":"7","key":"10.1016\/j.critrevonc.2026.105373_bib48","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2116133","article-title":"Axicabtagene ciloleucel as second-line therapy for large B-cell lymphoma","volume":"386","author":"Locke","year":"2022","journal-title":"N. Engl. J. Med"},{"issue":"16","key":"10.1016\/j.critrevonc.2026.105373_bib49","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa1407222","article-title":"Chimeric antigen receptor T cells for sustained remissions in leukemia","volume":"371","author":"Maude","year":"2014","journal-title":"N. Engl. J. Med"},{"key":"10.1016\/j.critrevonc.2026.105373_bib50","doi-asserted-by":"crossref","DOI":"10.1146\/annurev-immunol-032713-120136","article-title":"Adoptive immunotherapy for cancer or viruses","volume":"32","author":"Maus","year":"2014","journal-title":"Annu Rev. Immunol."},{"key":"10.1016\/j.critrevonc.2026.105373_bib51","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2024.122683","article-title":"The paths toward non-viral CAR-T cell manufacturing: A comprehensive review of state-of-the-art methods","volume":"348","author":"Metanat","year":"2024","journal-title":"Life Sci."},{"issue":"10","key":"10.1016\/j.critrevonc.2026.105373_bib52","doi-asserted-by":"crossref","DOI":"10.1038\/d41573-024-00150-z","article-title":"vivo CAR T cells move into clinical trials","volume":"23","author":"Mullard","year":"2024","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.critrevonc.2026.105373_bib53","doi-asserted-by":"crossref","DOI":"10.18609\/cgti.2025.077","article-title":"Targeting T cells in vivo: advances in non-viral gene delivery and clinical applications","author":"Nguyen","year":"2025","journal-title":"Cell Gene Ther. Insights"},{"issue":"9","key":"10.1016\/j.critrevonc.2026.105373_bib54","doi-asserted-by":"crossref","DOI":"10.1182\/blood.2024024523","article-title":"vivo CAR T-cell generation in nonhuman primates using lentiviral vectors displaying a multidomain fusion ligand","volume":"144","author":"Nicolai","year":"2024","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105373_bib55","doi-asserted-by":"crossref","DOI":"10.1016\/j.ymthe.2025.03.005","article-title":"From concept to cure: the evolution of CAR-T cell therapy","volume":"33","author":"Patel","year":"2025","journal-title":"Mol. Ther."},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105373_bib56","doi-asserted-by":"crossref","DOI":"10.3390\/ijms27041737","article-title":"Vivo CAR-T therapies-a new era of programmable immunity","volume":"27","author":"Pierini","year":"2026","journal-title":"Int. J. Mol. Sci."},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105373_bib57","doi-asserted-by":"crossref","DOI":"10.1016\/j.jcyt.2018.11.009","article-title":"Manufacturing chimeric antigen receptor T cells: issues and challenges","volume":"21","author":"Roddie","year":"2019","journal-title":"Cytotherapy"},{"issue":"6","key":"10.1016\/j.critrevonc.2026.105373_bib58","doi-asserted-by":"crossref","DOI":"10.1089\/dna.2022.0171","article-title":"Uniting disciplines to develop therapeutics: targeted mrna lipid nanoparticles reprogram the immune system in vivo to treat heart disease","volume":"41","author":"Rurik","year":"2022","journal-title":"DNA Cell Biol."},{"issue":"6576","key":"10.1016\/j.critrevonc.2026.105373_bib59","doi-asserted-by":"crossref","DOI":"10.1126\/science.abm0594","article-title":"CAR T cells produced in vivo to treat cardiac injury","volume":"375","author":"Rurik","year":"2022","journal-title":"Science"},{"issue":"6576","key":"10.1016\/j.critrevonc.2026.105373_bib60","doi-asserted-by":"crossref","DOI":"10.1126\/science.abm0594","article-title":"CAR T cells produced in vivo to treat cardiac injury","volume":"375","author":"Rurik","year":"2022","journal-title":"Science"},{"issue":"6576","key":"10.1016\/j.critrevonc.2026.105373_bib61","doi-asserted-by":"crossref","DOI":"10.1126\/science.abm0594","article-title":"CAR T cells produced in vivo to treat cardiac injury","volume":"375","author":"Rurik","year":"2022","journal-title":"Science"},{"issue":"10","key":"10.1016\/j.critrevonc.2026.105373_bib62","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22105084","article-title":"Contemporary transposon tools: a review and guide through mechanisms and applications of sleeping beauty, piggyBac and Tol2 for genome engineering","volume":"22","author":"Sandoval-Villegas","year":"2021","journal-title":"Int. J. Mol. Sci."},{"issue":"26","key":"10.1016\/j.critrevonc.2026.105373_bib63","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa1708566","article-title":"Chimeric antigen receptor T cells in refractory b-cell lymphomas","volume":"377","author":"Schuster","year":"2017","journal-title":"N. Engl. J. Med"},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105373_bib64","doi-asserted-by":"crossref","DOI":"10.3390\/ijms27020909","article-title":"Engineering immunity: current progress and future directions of CAR-T cell therapy","volume":"27","author":"Sioud","year":"2026","journal-title":"Int. J. Mol. Sci."},{"issue":"8","key":"10.1016\/j.critrevonc.2026.105373_bib65","doi-asserted-by":"crossref","DOI":"10.1021\/jacs.2c12893","article-title":"Ionizable Lipid Nanoparticles for In Vivo mRNA Delivery to the Placenta during Pregnancy","volume":"145","author":"Swingle","year":"2023","journal-title":"J. Am. Chem. Soc."},{"issue":"11","key":"10.1016\/j.critrevonc.2026.105373_bib66","doi-asserted-by":"crossref","DOI":"10.1016\/j.ymthe.2023.09.021","article-title":"Arming CAR-T cells with cytokines and more: Innovations in the fourth-generation CAR-T development","volume":"31","author":"Tang","year":"2023","journal-title":"Mol. Ther."},{"key":"10.1016\/j.critrevonc.2026.105373_bib67","unstructured":"Tumor Microenvironment Immunosuppression: A Roadblock to CAR T-Cell Advancement in Solid Tumors - PMC. Accessed January 31, 2026. \u3008https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC9688327\/?utm_source=chatgpt.com\u3009."},{"issue":"21","key":"10.1016\/j.critrevonc.2026.105373_bib68","doi-asserted-by":"crossref","DOI":"10.1097\/CM9.0000000000003706","article-title":"Innovative strategies for improving CAR-T cell therapy: a nanomedicine perspective","volume":"138","author":"Wang","year":"2025","journal-title":"Chin. Med. J."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105373_bib69","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2020.03.023","article-title":"CRISPR-based therapeutic genome editing: strategies and in vivo delivery by AAV vectors","volume":"181","author":"Wang","year":"2020","journal-title":"Cell"},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105373_bib70","doi-asserted-by":"crossref","DOI":"10.1093\/nar\/gkaf133","article-title":"Tuning the tropism and infectivity of SARS-CoV-2 virus-like particles for mRNA delivery","volume":"53","author":"Yang","year":"2025","journal-title":"Nucleic Acids Res"},{"issue":"6","key":"10.1016\/j.critrevonc.2026.105373_bib71","doi-asserted-by":"crossref","DOI":"10.1021\/acsomega.3c08353","article-title":"Lipid nanoparticle-based delivery system\u2500a competing place for mRNA vaccines","volume":"9","author":"Zhang","year":"2024","journal-title":"ACS Omega"},{"issue":"8","key":"10.1016\/j.critrevonc.2026.105373_bib72","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2022.03.023","article-title":"Modular design of synthetic receptors for programmed gene regulation in cell therapies","volume":"185","author":"Zhu","year":"2022","journal-title":"Cell"}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S104084282600260X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S104084282600260X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T13:05:13Z","timestamp":1783170313000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S104084282600260X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":72,"alternative-id":["S104084282600260X"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2026.105373","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"In vivo generation of CAR-T cells: Current obstacles, strategic solutions, and clinical translation","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2026.105373","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"105373"}}